It was recently reported that the mTOR pathway mediated the non-canonical Hh signaling cascade to induce PD-L1 expression [54], and that increased HH activity was a predictive biomarker for resistance to immune checkpoint inhibitors in diverse cancers [51]. This evidence concerns the gene CD274 and cancer.